Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03682796 · ClinicalTrials.gov registry record · Phase 1

Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma

A Phase 1 study of Lymphoma and Lymphoma, Non-Hodgkin, sponsored by Triphase Research and Development III.

Completed
Registry status
Phase 1
Development phase
32
Enrollment target
7
Study locations

NCT03682796 is a Phase 1 study of Lymphoma and Lymphoma, Non-Hodgkin that has completed, run by Triphase Research and Development III. The registered enrollment target is 32 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (93% lower). The trial reports 7 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03682796, a Phase 1 study of Lymphoma and Lymphoma, Non-Hodgkin, has completed, sponsored by Triphase Research and Development III.

COMPLETED
Registry status
Phase 1
Development phase
32 participants
Enrollment target
7
Study locations

Study Summary

This is a Phase 1, multi-center, open-label study of TRPH-222 monotherapy in subjects with relapsed and/or refractory B-cell NHL. The study will be conducted in two Stages: Dose-Escalation, Dose-Expansion.

Conditions Studied

Lymphoma Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Large B-Cell, Diffuse Lymphoma, Follicular Lymphoma, Mantle-Cell Lymphoma, Marginal Zone

Interventions

  • DRUG TRPH-222

Study Locations (7)

Arizona

  • Banner MD Anderson - Gilbert

New York

  • Roswell Park Comprehensive Cancer Center - Buffalo

Ohio

  • Ohio State University Comprehensive Cancer Center - Columbus

Pennsylvania

  • Abramson Cancer Center of the University of Pennsylvania - Philadelphia

Tennessee

  • Sarah Cannon Research Institute at Tennessee Oncology - Nashville

Ontario

  • Princess Margaret Cancer Centre - Toronto

Quebec

  • Jewish General Hospital - Montreal

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2018-10-15
Est. Completion 2021-11-17
Phase Phase 1

Sponsor

Triphase Research and Development III

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03682796

The ClinicalTrials.gov registry entry for NCT03682796 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (93% lower). The listed sponsor is Triphase Research and Development III, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which TRPH-222 is the first listed.

NCT03682796 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Arizona, New York, Ohio.

Frequently Asked Questions

What is clinical trial NCT03682796 about?

NCT03682796 is a clinical study titled "Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma". This is a Phase 1, multi-center, open-label study of TRPH-222 monotherapy in subjects with relapsed and/or refractory B-cell NHL. The study will be conducted in two Stages: Dose-Escalation, Dose-Expansion.

What is the current status of trial NCT03682796?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2018-10-15. Estimated completion is 2021-11-17.

What conditions does trial NCT03682796 study?

This clinical trial studies the following conditions: Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular.

What interventions are being tested in trial NCT03682796?

The interventions under investigation include: TRPH-222 (DRUG).

Who is sponsoring clinical trial NCT03682796?

This trial is sponsored by Triphase Research and Development III, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03682796 being conducted?

This trial has 7 study locations across Arizona, New York, Ohio, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lymphoma

All registered trials for this condition

Lymphoma, Non-Hodgkin

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.